Next Article in Journal
Muscle–Bone Crosstalk: Emerging Opportunities for Novel Therapeutic Approaches to Treat Musculoskeletal Pathologies
Next Article in Special Issue
The Role of Anti-Thymocyte Globulin or Alemtuzumab-Based Serotherapy in the Prophylaxis and Management of Graft-Versus-Host Disease
Previous Article in Journal / Special Issue
A Critical Appraisal of Extracorporeal Photopheresis as a Treatment Modality for Acute and Chronic Graft-Versus-Host Disease
Article Menu

Export Article

Open AccessReview
Biomedicines 2017, 5(4), 61; doi:10.3390/biomedicines5040061

The Role of B Cell Targeting in Chronic Graft-Versus-Host Disease

Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
*
Author to whom correspondence should be addressed.
Received: 21 August 2017 / Revised: 20 September 2017 / Accepted: 9 October 2017 / Published: 17 October 2017
(This article belongs to the Special Issue Cell Therapy for the Treatment of GVHD)
View Full-Text   |   Download PDF [227 KB, uploaded 18 October 2017]

Abstract

Chronic graft-versus-host disease (cGVHD) is a leading cause of late morbidity and mortality following allogeneic stem cell transplantation. Current therapies, including corticosteroids and calcineurin inhibitors, are only effective in roughly 50% of cases; therefore, new treatment strategies are under investigation. What was previously felt to be a T cell disease has more recently been shown to involve activation of both T and B cells, as well as a number of cytokines. With a better understanding of its pathophysiology have come more expansive preclinical and clinical trials, many focused on B cell signaling. This report briefly reviews our current understanding of cGVHD pathophysiology and reviews clinical and preclinical trials with B cell-targeted agents. View Full-Text
Keywords: chronic graft-versus-host disease; B cell; rituximab; ibrutinib chronic graft-versus-host disease; B cell; rituximab; ibrutinib
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Rhoades, R.; Gaballa, S. The Role of B Cell Targeting in Chronic Graft-Versus-Host Disease. Biomedicines 2017, 5, 61.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top